Skip to main content

Dermatology

RheumNow Podcast square

What Worries You, Masters You (7.1.2022)

Jul 01, 2022

Dr. Jack Cush reviews recent news, regulatory and guideline updates from the past week on RheumNow.com.  Studies on methotrexate use, COVID vaccination, Supplements and vitamins, and arthrocentesis despite anticoagulation are discussed.




  1. FDA approved Abbvies risakizumab-rzaa

Read Article
GRAPPA,PsA,guideline

New Updated GRAPPA Psoriatic Arthritis Recommendations

Jun 29, 2022

The GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis) treatment recommendations have been updated and the 2021 evidence-based guidance is rich in treatment recommendations based on the key disease "domains" - peripheral arthritis, axial disease, enthesitis,

Read Article
hudsonpsoriasis.jpg

Bimekizumab Safety in Psoriasis Patients

Jun 23, 2022

A pooled analyses of data from eight, phase 2 and 3 randomized clinical trials shows bimekizumab, a dual IL-17A/F inhibitor, to be effective in plaque psoriasis and was well tolerated aside from an increased incidence of mild to moderate oral candidiasis. 



The cohort included 1789

Read Article
sun.jpg

Does Sunlight Trigger Lupus?

MedPage Today
Jun 22, 2022

Whether exposure to ultraviolet (UV) radiation from the sun can cause new-onset systemic lupus erythematosus (SLE) wasn't settled by data from a large, long-running epidemiologic study, but the trends indicated that it could.

Read Article
Jakne (acne) with upadacitinib: review of 857 Psoriasis pts on UPA by wk 16 9.8-15.2% c/o mild/moderate acne; only 2 D/C for acne. Higher rates seen among younger, female, non-White patients. (This rare in RA!) https://t.co/cN6NU7e5sb https://t.co/JAMYS8EIwN
Dr. John Cush @RheumNow( View Tweet )
Jun 20, 2022
RheumNow Podcast square

Two Week Twitter (6.17.2022)

Jun 17, 2022

Dr. Jack Cush does a 2-week review of RheumNow Tweets on news and journal citations worth noting, along with some opinions on Telehealth, manpower, monkeypox and the price of drugs.




  1. Although Rheumatology currently ranks 2nd or 3rd in specialty use of telemedicine - the vast

Read Article
JAK Janus

JAK/STAT pathway in pyoderma gangrenosum: a new therapeutic highway?

Pyoderma gangrenosum (PG) is rare, but often associated with different forms of arthritis, in particular rheumatoid arthritis and inflammatory bowel diseases. 

Read Article
Smile feedback opinion yes no good back opinion

What do our lupus patients think about treat-to-target?

In SLE, two targets that are increasingly used are the DORIS 2021 Remission and the Lupus Low Disease Activity (LLDAS). T2T is more likely to be successful if the treating clinicians and the patients set the treatment goals together. What do our patients think about T2T and do they have any say/

Read Article
guidelines.recommendations.jpg

BSR Guideline for Psoriatic Arthritis - 2022 Update

Jun 06, 2022

The British Society of Rheumatology has published their updated 2022 recommendations for the use of biologics and targeted synthetic treatments in patients iwth psoriatic arthritis. These guidelines follow initial treatment with a single conventional systemic disease-modifying anti-rheumatic

Read Article
Psoriasis and Psoriatic arthritis patients have different circulating microRNA signatures compared to healthy controls. (miRNAs: non-coding RNAs controlling gene expression) PsO/PsA miRNAs involved in bone metabolism @RheumNow #EULAR2022 ABST#POS0314

Robert B Chao, MD @doctorRBC( View Tweet )

Jun 04, 2022
Large French study of over 23k patients with either PsA or PsO showed a longer persistence (time of initiation to discontinuation) in those who took IL-17i vs. TNFi for PsA and PsO pts. IL-17i longer than IL-12/23i in PsA pts. @RheumNow #EULAR2022 ABST#POS0075 https://t.co/rH1g4fPUYC
Robert B Chao, MD @doctorRBC( View Tweet )
Jun 02, 2022
No longer a "seronegative" disease? Serological collagen biomarkers (degradation markers of type I and VI collagen) can differentiate PsO pts from PsA. Potential biomarkers of MSK involvement? @RheumNow #EULAR2022 ABST#OP0031 https://t.co/vS6mD5PUxw
Robert B Chao, MD @doctorRBC( View Tweet )
Jun 01, 2022
Phase 3 RCT upadacitinib in nrAxSpA. Clinical (ASAS40), PRO, and radiologic response seen at week 14 vs placebo @RheumNow #EULAR2022 OP0016 https://t.co/s3Vf4QiiAD https://t.co/gzlxZ3sxHF
Richard Conway @RichardPAConway( View Tweet )
Jun 01, 2022
#Bestinclass #EULAR2022 #PsA @RheumNow #OP0027 #CVE #MACE with #Tofacitinib in #psoriatic #arthritis and #PsO with median 3 to 4 yrs Rx. 40% metabolic syndrome which is high. There was no comparison. As expected hose with ⬆️MACE risks had more outcomes. https://t.co/sTjFHsUxzi
Jun 01, 2022
child.guttate.psoriasis

Psoriasis and Nonalcoholic Fatty Liver Disease

May 26, 2022

A large US population based study shows that psoriasis is associated with a higher risk of nonalcoholic fatty liver disease (NAFLD).



The study included 5672 US patients, aged 20 to 59 years from the National Health and Nutrition Examination Survey. The main outcome was NAFLD, defined

Read Article
Long,covid

Long COVID Manifestations

MMWR
May 24, 2022

The acute consequences of a SARS-CoV-2 infection may be bothersome or devastating, but the long-term consequences may lead to so-called "long COVID" syndrome.  Long COVID appears to affect up to 20% of those who survive COVID-19 infection. 

Read Article
PSS.hands_.Raynauds.jpg (keep)

Relevance of Raynaud’s in Systemic Sclerosis

May 18, 2022

Raynaud’s phenomenon (RP) is integral to the diagnosis and management of systemic sclerosis (SSc) patients; a recent analysis suggests that RP should be characterized based on color change and the presence of other symptoms to know whether RP portends more serious manifestations.

Read Article
SpA,RNL,2022

RNL 2022: Spondyloarthritis Spectrum

May 18, 2022

This RheumNow Live 2022 session features highlights from lectures on Spondyloarthritis.



- Microbiome in Spondyloathritis - Jose Scher, MD



- Axial Psoriatic Arthritis - Philip Mease, MD



- Juvenile Spondyloathritis - Pamela Weiss, MD


Read Article
Acne with JAK Inhibitors JAK inhibitors have become enormously popular and while their side effect profile has been delineated and reviewed, little mention is made of acne – an adverse event that may affect up to one-quarter of patients taking JAKi.https://t.co/ADzaBjgsAN https://t.co/Yydo47UGYl
Dr. John Cush @RheumNow( View Tweet )
May 14, 2022
RheumNow Podcast square

Methotrexate Monitoring (5.13.2022)

May 13, 2022

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Bad news for digitial ulcers in Systemic sclerosis, Readmissions in Lupus and Thrombocytopenia in APL patients.




  1. Risk factors for readmission among 132,400 #SLE hospitalizatiions included

Read Article
Large Korean population study compares pts w/ palmoplantar psoriasis vs psoriasis and PPP pts have more risk for ankylosing spondylitis (aOR 1.37) & Graves dz (aOR 1.4) but lower risk for PsA (aOR 0.54), SLE (0.67); Sjögren (0.70); vitiligo (0.53) https://t.co/0fv2vnFBPf https://t.co/PJMagIeZ2F
Dr. John Cush @RheumNow( View Tweet )
May 07, 2022
Danish case-control registry of 491,274 women shows Psoriasis assoc w/ increased risk of ectopic pregnancy (EP) (OR 1.34), highest in women w/ moderate-to-severe psoriasis (OR 2.77). EP risk was 2.5x higher for women w/ mod--severe PSO https://t.co/vUtNEMDOhr

Dr. John Cush @RheumNow( View Tweet )

May 06, 2022
RheumNow Podcast square

What is JAKne? (5.6.2022)

May 06, 2022

Dr. Jack Cush reviews the news, journal reports, FDA actions, new side effects and changing prevalence of Gout.




  1. Gout affects >10 million (4%) in USA, but now w/ more ethnicity, with highest risk in Native Hawaiians (HR 2.21), followed by Black (1.34) and Japanese (1.14);

Read Article
acne

Acne with JAK Inhibitors

May 05, 2022

JAK inhibitors have become enormously popular and while their side effect profile has been delineated and reviewed, little mention is made of acne – an adverse event that may affect up to one-quarter of patients taking JAK inhibitors (JAKi).

Read Article
RheumNow Podcast square

$30 Billion and Counting (4.29.2022)

Apr 29, 2022

Dr. Jack Cush reviews the news and journal reports and takes viewer questions this week.

Read Article
×